Clovis Oncology Inc. (NASDAQ:CLVS) shares traded up 1.4% on Friday . The stock traded as high as $14.19 and last traded at $14.08, with a volume of 256,629 shares trading hands. The stock had previously closed at $13.89.

Several research analysts recently weighed in on the company. Credit Suisse Group AG reaffirmed a “hold” rating on shares of Clovis Oncology in a research note on Tuesday. Stifel Nicolaus reiterated a “buy” rating and issued a $30.00 price target on shares of Clovis Oncology in a research report on Thursday, June 30th. Piper Jaffray Cos. reiterated a “hold” rating and issued a $14.00 price target on shares of Clovis Oncology in a research report on Wednesday, June 29th. Vetr upgraded Clovis Oncology from a “buy” rating to a “strong-buy” rating and set a $17.71 price target for the company in a research report on Thursday, June 9th. Finally, Zacks Investment Research lowered Clovis Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. Seven equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Clovis Oncology presently has a consensus rating of “Hold” and a consensus target price of $29.25.

The firm has a 50 day moving average price of $14.65 and a 200-day moving average price of $18.08. The stock’s market capitalization is $552.36 million.

Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.39) by $0.22. During the same period in the prior year, the company posted ($1.86) EPS. The firm’s revenue was up NaN% compared to the same quarter last year. On average, analysts anticipate that Clovis Oncology Inc. will post ($8.00) earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Trexquant Investment LP purchased a new stake in Clovis Oncology during the fourth quarter worth $3,170,000. ProShare Advisors LLC increased its stake in Clovis Oncology by 9.5% in the fourth quarter. ProShare Advisors LLC now owns 36,129 shares of the biopharmaceutical company’s stock worth $1,265,000 after buying an additional 3,125 shares in the last quarter. Rhumbline Advisers increased its stake in Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 1,880 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock worth $1,806,000 after buying an additional 889 shares in the last quarter.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.